Gewinn- und Verlustrechnung von UnitedHealth Group Incorporated

UNH heads into Q3 with investors focused on whether medical-cost gains can hold as Medicare Advantage margins improve without deeper member losses.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

UnitedHealth Group (UNH) has rebounded from $300 to $440-$450, with fundamental recovery in margins, Medicare Advantage, and Optum Health now largely realized. I now rate UNH a Sell, as the risk/reward has flipped: valuation offers little margin of safety, and the market prices in recovery and future growth. Further upside depends on flawless execution amid persistent medical cost inflation and ongoing challenges in Commercial and Medicaid segments.

General Partner Inc. acquired a new stake in shares of UnitedHealth Group Incorporated (NYSE: UNH) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,396 shares of the healthcare conglomerate's stock, valued at approximately $512,000. Other hedge funds and other institutional investors

Heartwood Wealth Advisors LLC acquired a new position in shares of UnitedHealth Group Incorporated (NYSE: UNH) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,471 shares of the healthcare conglomerate's stock, valued at approximately $1,641,000. Several other large

UnitedHealth is exiting select Medicare Advantage plans for 2027 as rising medical costs pressure profitability, reshaping its membership mix.

Texas Attorney General Ken Paxton has sent civil investigative demands to the company to collect evidence around potential violations of the Texas Deceptive Trade Practices Act, according to his office.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

UnitedHealth Group (UNH) remains a Buy, with fundamentals improving and valuation at a decade low P/E of 19.95 despite peer discounts. Key Q3 focus areas include commercial cost trends, star ratings, cash flow guidance, and Optum's performance amid shrinking insured books. UNH's FCF yield is at a nine-year high (7.1%), and its robust revenue CAGR and margins highlight scale advantages.

Violich Capital Management Inc. lifted its stake in shares of UnitedHealth Group Incorporated (NYSE: UNH) by 15.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 36,134 shares of the healthcare conglomerate's stock after acquiring an additional 4,880 shares during the quarter.